Anzeige
Mehr »
Montag, 08.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PY7P | ISIN: US07373V1052 | Ticker-Symbol:
NASDAQ
05.09.25 | 21:59
20,890 US-Dollar
+12,68 % +2,350
1-Jahres-Chart
BEAM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BEAM THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur BEAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.08.Cantor Fitzgerald reiterates Overweight rating on Beam Therapeutics stock38
14.08.Beam Therapeutics stock surges after FDA grants RMAT designation17
14.08.Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease302CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
► Artikel lesen
05.08.Clear Street reiterates Buy rating on Beam Therapeutics stock at $346
05.08.Clear Street hält an Kaufempfehlung für Beam Therapeutics mit Kursziel von 34 US-Dollar fest9
05.08.Beam Therapeutics Inc. - 10-Q, Quarterly Report2
05.08.Beam Therapeutics Inc. - 8-K, Current Report2
05.08.Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)346With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile...
► Artikel lesen
BEAM THERAPEUTICS Aktie jetzt für 0€ handeln
06.07.H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT14
03.07.Beam Therapeutics Inc. - 8-K, Current Report2
01.07.H.C. Wainwright bekräftigt Kaufempfehlung für Beam Therapeutics mit Kursziel von 80 US-Dollar26
01.07.H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target1
16.06.H.C. Wainwright reiterates buy rating on Beam Therapeutics stock10
13.06.Beam Therapeutics reports positive data from sickle cell therapy trial7
13.06.Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress541Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients...
► Artikel lesen
06.06.Beam Therapeutics Inc. - 8-K, Current Report5
03.06.Beam Therapeutics Announces Orphan Drug Designation For BEAM-101534WASHINGTON (dpa-AFX) - Beam Therapeutics (BEAM) announced that the FDA has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment...
► Artikel lesen
03.06.Beam Therapeutics' BEAM-101 receives FDA orphan drug status for SCD treatment2
29.05.Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)1.242CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
► Artikel lesen
14.05.Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress19
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1